Hepatotoxicity from arsenic trioxide for pediatric acute promyelocytic leukemia

Journal of Pediatric Hematology/Oncology

Volumn 35, Issue 2, 2013, Pages

  Hao, Liangchun ^a   Zhao, Jishu ^a   Wang, Xiuli ^a   Wang, Hong ^a   Wang, Huan ^a   Xu, Gang ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

Author keywords

acute; arsenic trioxide (As2O3); hepatotoxicity; leukemia; premyelocyte

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTHRACYCLINE; ARSENIC TRIOXIDE; ASPARTATE AMINOTRANSFERASE; GAMMA GLUTAMYLTRANSFERASE; LACTATE DEHYDROGENASE;

AGE; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CHILD; CLINICAL ARTICLE; CORRELATION ANALYSIS; DISEASE DURATION; DISSEMINATED INTRAVASCULAR CLOTTING; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GENDER; HEPATOMEGALY; HUMAN; INCIDENCE; LACTATE DEHYDROGENASE BLOOD LEVEL; LIVER DYSFUNCTION; LIVER FUNCTION TEST; MALE; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; SCHOOL CHILD; TOXIC HEPATITIS;

ANTINEOPLASTIC AGENTS; ARSENICALS; CHILD; HODGKIN DISEASE; HUMANS; LEUKEMIA, PROMYELOCYTIC, ACUTE; LIVER; MALE; OXIDES;

EID: 84874496908     PISSN: 10774114     EISSN: 15363678     Source Type: Journal    
DOI: 10.1097/MPH.0b013e31827e91bc     Document Type: Article

References (23)

1. Wang ZY, Chen Z. Acute promyelocytic leukemia: from highly fatal to highly curable. Blood. 2008;111:2505-2515.
2. Tallman MS, Altman JK. How I treat acute promyelocytic leukemia. Blood. 2009;114:5126-5135.
3. Chou WC, Dang CV. Acute promyelocytic leukemia: recent advances in therapy and molecular basis of response to arsenic therapies. Curr Opin Hematol. 2005;12:1-6.
4. Hu J, Liu YF, Wu CF, et al. Long-term efficacy and safety of all-trans retinoic acid/arsenic trioxide-based therapy in newly diagnosed acute promyelocytic leukemia. PNAS. 2009; 106:3342-3347.
5. George B, Mathews V, Poonkuzhali B, et al. Treatment of children with newly diagnosed acute promyelocytic leukemia with arsenic trioxide: a single center experience. Leukemia. 2004;18:1587-1590.
6. Mathews V, Jijina F, Ross C, et al. Single agent arsenic trioxide regimen for the treatment of newly diagnosed acute promyelocytic leukemia: a multicenter randomized controlled study from India to study the optimal duration of arsenic trioxide maintenance therapy (IAPLSG04). Blood. 2009; 114:822, abst 2082.
7. Thirugnanam R, George B, Chendamarai E, et al. Comparison of clinical outcomes of patients with relapsed acute promyelo-cytic leukemia induced with arsenic trioxide and consolidated with either an autologous stem cell transplant or an arsenic trioxide-based regimen. Biol Blood Marrow Transplant. 2009; 15:1479-1484.
8. Sanz MA, Lo-Coco F. Arsenic trioxide, its use in the treatment of acute promyelocytic leukemia. Am J Cancer. 2006;5:183-191.
9. 3) in the treatment of patients with acute promyelocytic leukemia: the M. D. anderson experience. Cancer. 2003; 97:2218-2224.
10. Mathews V, Desire S, George B, et al. Hepatotoxicity profile of single agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia, its impact on clinical outcome and the effect of genetic polymorphisms on the incidence of hepatotoxicity. Leukemia. 2006;20:881-883.
11. Zhou J, Zhang YM, Li JM, et al. Single-agent arsenic trioxide in the treatment of children with newly diagnosed acute promyelocytic leukemia. Blood. 2010;115:1697-1702.
12. Sanz MA. Arsenic trioxide in the treatment of acute promyelocytic leukemia. A review of current evidence. Haematologica. 2005;90:1231-1235.
13. Mathews V, George B, Lakshmi KM, et al. Single agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: durable remissions with minimal toxicity. Blood. 2006;107:2627-2632.
14. Wang H, Chen XY, Wang BS, et al. The efficacy and safety of arsenic trioxide with or without all-transretinoic acid for the treatment of acute promyelocytic leukemia: a meta-analysis. Leuk Res. 2011;35:1170-1177.
15. Ghavamzadeh A, Alimoghaddam K, Ghaffari SH, et al. Treatment of acute promyelocytic leukemia with arsenic trioxide without ATRA and/or chemotherapy. Ann Oncol. 2006;17:131-134.
16. 3) on event-free survival (EFS) and overall survival (OS) among patients with newly diagnosed acute promyelo-cytic leukemia (APL): North American Intergroup Protocol C9710. Proc Am Soc Clin Oncol. 2007;25:1S.
17. Lengfelder E, Saussele S, Weisser A, et al. Treatment concepts of acute promyelocytic leukemia. Crit Rev Oncol Hematol. 2005;56:261-274.
18. Mathews V, Balasubramanian P, Shaji RV, et al. Arsenic trioxide in the treatment of newly diagnosed acute promyelo-cytic leukemia: a single center experience. Am J Hematol. 2002;70:292-299.
19. Estey EH, Hutchinson F. Newly diagnosed acute promyelo-cytic leukemia: arsenic moves front and center. J Clin Oncol. 2011;29:2743-2746.
20. Ghavamzadeh A, Alimoghaddam K, Rostami S, et al. Phase II study of single-agent arsenic trioxide for the front-line therapy of acute promyelocytic leukemia. J Clinic Oncol. 2011;29: 2753-2757.
21. Keyhani M. Use of arsenic trioxide as a first-line single agent in the treatment of acute promyelocytic leukemia. J Clinic Oncol. 2012;30:217.
22. Mathews V, George B, Chendamarai E, et al. Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: long-term follow-up data. J Clinic Oncol. 2010;28:3866-3871.
23. Soignet SL, Frankel SR, Douer D, et al. United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. J Clin Oncol. 2001;19:3852-3860.